W. Jeong

发表

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors

J. Doroshow, A. Chen, E. Polley, 2015, Investigational New Drugs.

Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors

S. Steinberg, P. Choyke, J. Doroshow, 2014, Investigational New Drugs.

Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors.

J. Doroshow, A. Chen, S. Kummar, 2014 .

US FDA Approved Oral Kinase Inhibitors for the Treatment of Malignancies

J. Doroshow, S. Kummar, W. Jeong, 2013 .

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors

L. Rubinstein, J. Doroshow, A. Chen, 2021, Investigational New Drugs.

High-Dose Cytarabine-Mitoxantrone Versus Hyper-CVAD in Adult Acute Lymphoblastic Leukemia and Burkitt’s Lymphoma: A Single Center Experience of Two Induction Regimens

K. Seiter, Q. Shi, Delong Liu, 2009 .

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis

G. Shapiro, J. Tabernero, S. Fudio, 2020, Cancer Chemotherapy and Pharmacology.

PET scan-positive cat scratch disease in a patient with T cell lymphoblastic lymphoma.

T. Ahmed, K. Seiter, Delong Liu, 2005, Leukemia research.

Burned-Out Testicular Germ Cell Tumor Presenting as Retroperitoneal Lymphadenopathy in a Patient With Cryptorchidism: A Case Report & Review of Literature

W. Jeong, Shan Guo, S. Shahrokh, 2022, Cureus.

Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update

Michael Kahn, M. Kahn, Sherry X. Yang, 2015, Nature Reviews Clinical Oncology.

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

S. Steinberg, P. Choyke, J. Doroshow, 2014, Cancer Chemotherapy and Pharmacology.

United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.

J. Doroshow, S. Kummar, W. Jeong, 2013, Current problems in cancer.

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.

Marilyn M. Li, T. Burns, S. Ramalingam, 2019, Lung cancer.

Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors

M. Birrer, H. Borghaei, U. Matulonis, 2017, Cancer.

Phase 1 study of IMGN853, a folate receptor alpha (FR{alpha})-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.

A. Oza, M. Birrer, H. Borghaei, 2015 .

Preliminary single agent activity of IMGN853, a folate receptor alpha (FR{alpha})-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.

A. Oza, M. Birrer, R. Perez, 2015 .

Abstract 2416: Weekly EZN-2208 (pegylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.

J. Doroshow, A. Chen, B. Turkbey, 2013 .